Management is focused on stabilizing the transthyretin fibrils in the myocardium, in addition to the guideline-directed medical therapy (GDMT) for heart failure, to prevent the worsening deleterious outcome of untreated transthyretin cardiac amyloidosis. The gene discussed is TTR; the disease is heart failure.